Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Loree Easley

Physician Assistant Bartlett, TN Physician Assistant

NPI 1417108259 CMS profile 11061902

6644 Summer Knoll Cir, Bartlett, TN 38134

Open in the dashboard

General payments

$186,557

1,308 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$22,343 paid to institutions, not to them · program year 2021

Through program year 2025, Loree Easley of Bartlett, TN is reported in the CMS Open Payments database as having received $186,557 across 1,308 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $22,343 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 99th percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $42,046 269
2024 General $67,938 348
2023 General $40,331 293
2022 General $22,421 253
2021 General $13,821 145

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Loree Easley
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Loree Easley were reported at $42,046. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Loree Easley Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $13,821 $132 $37–$438 $132
2022 $22,421 $155 $48–$522 $149
2023 $40,331 $167 $52–$557 $160
2024 $67,938 $178 $55–$600 $164
2025 $42,046 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Janssen Biotech, Inc. $43,780 166 payments
  2. UCB, Inc. $34,328 106 payments
  3. AbbVie, Inc. $27,317 274 payments
  4. Galderma Laboratories, L.P. $26,158 77 payments
  5. Janssen Scientific Affairs, LLC $18,710 22 payments
  6. Sun Pharmaceutical Industries Inc. $11,400 43 payments
  7. E.R. Squibb & Sons, L.L.C. $6,629 62 payments
  8. Arcutis Biotherapeutics, Inc. $5,285 36 payments
  9. Novartis Pharmaceuticals Corporation $4,107 61 payments
  10. LEO Pharma Inc. $2,126 44 payments
  11. Other $6,718 417 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $131,916 94 payments
  2. Food and Beverage $22,183 1,114 payments
  3. Consulting Fee $16,177 12 payments
  4. Travel and Lodging $15,525 71 payments
  5. Education $726 16 payments
  6. Honoraria $31 1 payment
Products named General payments · program years 2021–2025
  1. TREMFYA $62,081 161 payments
  2. Bimzelx $17,771 72 payments
  3. SKYRIZI Immunology $12,679 154 payments
  4. Winlevi $10,766 14 payments
  5. AKLIEF Acne $9,946 16 payments
  6. SKYRIZI Immunology $7,234 45 payments
  7. RINVOQ $7,023 45 payments
  8. AKLIEF Acne $6,672 12 payments
  9. Cimzia $6,501 21 payments
  10. TWYNEO $6,489 6 payments
  11. Other $39,063 949 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 19 drugs

Part D claims

513

Median for Physician Assistant: 241

Drug cost

$776,833

Median for Physician Assistant: $4,110

Branded share of claims

19.7%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Skyrizi Pen Risankizumab-Rzaa Brand 24 $483,584
Stelara Ustekinumab Brand 11 $195,330
Dupixent Syringe Dupilumab Brand 24 $86,389
Clobetasol Propionate Generic 48 $3,144
Metronidazole Generic 19 $1,475
Doxycycline Hyclate Generic 63 $1,292
Ketoconazole Generic 70 $1,085
Triamcinolone Acetonide Generic 55 $916
Nystatin Generic 42 $788
Valacyclovir Valacyclovir Hcl Brand 20 $491

The 10 drugs with the highest cost, of 19 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 50 billing codes

Paid by Medicare

$157,780

Of which drugs: $6,514

Medicare patients

1,081

Average age 74

Services billed

3,578

634 women, 447 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 46%
Diabetes 29%
Ischemic heart disease 29%
Atrial fibrillation 17%
Chronic kidney disease 17%
Cancer 16%
Depression 13%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 11 34 $20

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 29 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
TREMFYA
$17,263 — —
Bimzelx
$14,388 — —
Winlevi
$10,567 — —
SKYRIZI
$9,558 24 —
RINVOQ
$4,936 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 29 with Patron

Records

1,308 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in Tennessee

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record